Source: Press Releases
February 05, 2021
2 min read

CooperVision, Essilor to commercialize SightGlass myopia control lenses

Source: Press Releases
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

CooperCompanies and EssilorLuxottica announced a partnership to accelerate commercialization of SightGlass Vision spectacle lenses, which are designed to slow the progression of myopia in children, according to press releases from the companies.

“Our collaboration with Essilor delivers on our promise to make myopia management accessible and the standard of care for treating childhood myopia,” CooperVision President Daniel McBride, said in a release. "With the SightGlass Vision technology from this collaboration, MiSight 1 day and orthokeratology contact lenses from CooperVision, and Stellest lenses from Essilor, [eye care professionals (ECPs)] can create a comprehensive optical intervention portfolio to treat the growing number of children impacted by myopia. ECPs and caregivers need access to a range of effective treatments, and we are committed to bringing effective products to market for them.”

Results from CooperVision’s Global Myopia Attitudes and Awareness Study indicated that 82% of ECPs were concerned that young patients will have significant eye health issues associated with myopia as they age, yet more than half reported that parents lack an understanding of these health risks. Once the risks were explained, 87% of parents were interested in learning about myopia management.

SightGlass Vision reported data from the randomized, controlled CYPRESS clinical study, which included 256 children 6 to 10 years old with myopia between –0.75 D and –4.50 D. Results showed that patients who wore SightGlass Vision Diffusion Optics Technology (DOT) lenses for a 12-month period had clinically stable visual acuity, a significant reduction in myopia progression between 59% and 74%, and a significant reduction in axial length progression between 33% and 50% compared with the control group.

“We have a shared commitment to advancing evidence-based myopia management technologies,” Thomas Chalberg, PhD, SightGlass founder and CEO, said in a release. “This groundbreaking collaboration only adds to our confidence about the future of the technology, the potential for the category and the millions of children whose myopia progression could be slowed.”

SightGlass Vision DOT lenses received the CE Mark in June 2020 and have been approved for sale in Canada. The joint venture with EssilorLuxottica will acquire SightGlass Vision from CooperCompanies.

“We are excited to join forces with CooperCompanies, a company with a strong track record in addressing major vision conditions, including myopia, and leverage together the SightGlass Vision technology,” EssilorLuxottica CEO Francesco Milleri, and deputy CEO Paul du Saillant, said in a press release. “This partnership is fully consistent with EssilorLuxottica’s strategy to improve access to vision care, including solutions that can control myopia progression. The complementarity of our existing solutions, including Essilor’s recent Stellest lens, with SightGlass Vision’s promising technology will further strengthen our offer by providing advanced products answering to the growing needs of customers and consumers worldwide.”